CIVICs Influenza Research

CIVICs research explores the biology of influenza viruses, characterizes immune responses during vaccination & infection, & develops cutting-edge vaccines to elicit broadly protective & long-lasting immunity to combat influenza.





123 **No. of CIVICs papers in the top 25% of their subject**
determined by SCImago Journal Rank quartile scores

2.06 **Avg. Relative Citation Ratio**
1.0 is greater than 50% of NIH-funded papers

Research Network

738 Authors — **142** Institutions — **68** Papers with external collaborators



The author network shows researchers linked by co-publishing history on CIVICs influenza papers, highlighting the collaborative nature of the program.

Authors from 2-4 distinct institutions

Author bridging research groups

Authors from 5-9 distinct institutions

Research Foci



Analysis of Medical Subject Heading (MeSH) terms in CIVICs influenza publications reveals the top 10 topics.

1. **Model Systems & Hosts**
   Animals | Humans | Mice
2. **Influenza Vaccine Immunology**
   Influenza Vaccines / Immunology | Influenza Vaccines | Female
3. **Hemagglutinin & Antibody Response**
   Hemagglutinin Glycoproteins, Influenza Virus / Immunology | Broadly Neutralizing Antibodies / Immunology | Vaccines, Inactivated / Immunology
4. **Neuraminidase & *in vitro* Systems**
   Neuraminidase / Immunology | Antibodies, Viral / Metabolism | Dogs
5. **Viral Agents & Glycosylation**
   Influenza A Virus, H3N2 Subtype / Immunology | Antigens, Viral / Immunology | Glycosylation
6. **Biochemistry & Viral Entry**
   Hemagglutinin Glycoproteins, Influenza Virus / Chemistry | Virus Internalization | Vaccines, Synthetic / Immunology
7. **Lung & Local Immune Responses**
   Lung / Immunology | Lung / Virology | Administration, Intranasal
8. **SARS-CoV-2 & COVID-19**
   SARS-CoV-2 | COVID-19 | Vaccines
9. **Cellular & Humoral Immunity**
   Antibodies, Neutralizing | Nanoparticles | CD4 Positive T Lymphocytes
10. **Metabolism & Immunology**
    Influenza, Human / Metabolism | B Lymphocytes / Immunology | Orthomyxoviridae Immunology

Publications

CIVR-HRP evaluated COBRA H1 & H3 HA antigens. Bivalent & monovalent vaccine formulations elicited broadly-reactive antibodies in mice. PMID: 35289635

SEM CIVIC performed a Phase I trial evaluating chimeric hemagglutinin-based influenza vaccines, which have the potential to be broadly protective. PMID: 33288923

DCVC engineered epitope-enriched immunogens to expand B cell responses in mice, a step towards universal influenza vaccine efficacy. PMID: 36351401

Developed under Contract No. 75N93019C00078 & 75N93022F00001 from NIAID, entitled "CIVICs Statistical, Data Management Coordination Center (SDMCC)."
*This infographic includes data from the inception of the CIVICs program through March 9, 2023 (publications). | Learn more at www.niaidcivics.org